MY170746A - Parenteral norovirus vaccine formulations - Google Patents
Parenteral norovirus vaccine formulationsInfo
- Publication number
- MY170746A MY170746A MYPI2014000073A MYPI2014000073A MY170746A MY 170746 A MY170746 A MY 170746A MY PI2014000073 A MYPI2014000073 A MY PI2014000073A MY PI2014000073 A MYPI2014000073 A MY PI2014000073A MY 170746 A MY170746 A MY 170746A
- Authority
- MY
- Malaysia
- Prior art keywords
- vaccine formulations
- norovirus vaccine
- parenteral
- parenteral norovirus
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 241001263478 Norovirus Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 208000006339 Caliciviridae Infections Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506447P | 2011-07-11 | 2011-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY170746A true MY170746A (en) | 2019-08-27 |
Family
ID=47506489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014000073A MY170746A (en) | 2011-07-11 | 2012-07-11 | Parenteral norovirus vaccine formulations |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9801934B2 (https=) |
| EP (3) | EP2731621B1 (https=) |
| JP (2) | JP6208659B2 (https=) |
| KR (1) | KR102096937B1 (https=) |
| CN (3) | CN108567975A (https=) |
| AU (2) | AU2012282658B2 (https=) |
| BR (1) | BR112014000656A2 (https=) |
| CA (1) | CA2841356C (https=) |
| CL (1) | CL2014000082A1 (https=) |
| CR (2) | CR20190540A (https=) |
| DK (1) | DK3299030T3 (https=) |
| DO (2) | DOP2014000004A (https=) |
| EA (3) | EA029470B1 (https=) |
| EC (1) | ECSP14013201A (https=) |
| ES (2) | ES2656527T3 (https=) |
| GE (1) | GEP201706668B (https=) |
| HK (2) | HK1199202A1 (https=) |
| IL (1) | IL230356B (https=) |
| MA (1) | MA35414B1 (https=) |
| MX (2) | MX379496B (https=) |
| MY (1) | MY170746A (https=) |
| PE (1) | PE20140845A1 (https=) |
| PH (3) | PH12021551773A1 (https=) |
| PL (2) | PL3299030T3 (https=) |
| SG (1) | SG10201605644WA (https=) |
| TN (1) | TN2014000008A1 (https=) |
| UA (1) | UA117732C2 (https=) |
| WO (1) | WO2013009849A1 (https=) |
| ZA (2) | ZA201401012B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| CA2841356C (en) | 2011-07-11 | 2022-03-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| KR102649950B1 (ko) | 2013-10-03 | 2024-03-22 | 다케다 백신즈 인코포레이티드 | 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법 |
| US20160310412A1 (en) | 2013-12-16 | 2016-10-27 | Takeda Pharmaceutical Company Limited | Microneedle |
| CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
| GB201703644D0 (en) | 2017-03-07 | 2017-04-19 | Elopak As | Improvements in or relating to toller mounting arrangements |
| CN110603058A (zh) * | 2017-05-15 | 2019-12-20 | 扬森疫苗与预防公司 | 含有病毒的稳定组合物 |
| US11633467B2 (en) | 2018-02-15 | 2023-04-25 | Icon Genetics Gmbh | Immunogenic composition and vaccine for generating an immune response to norovirus |
| WO2019231712A1 (en) * | 2018-05-29 | 2019-12-05 | Stc.Unm | Virus-like particle compositions and methods of using same |
| CN109265542B (zh) * | 2018-09-27 | 2021-06-15 | 国药中生生物技术研究院有限公司 | 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用 |
| AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| BR112022013537A2 (pt) | 2020-01-08 | 2022-11-22 | Bharat Biotech Int Ltd | Composições de vacina viral e métodos de preparações das mesmas |
| US20240156942A1 (en) | 2021-03-29 | 2024-05-16 | Denka Company Limited | Peptide of Norovirus Origin, Polynucleotide, Antibody, Composition, Method for Identifying Neutralizing Epitope for Norovirus |
| US20240238401A1 (en) | 2021-05-21 | 2024-07-18 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| CN118252924A (zh) * | 2022-12-27 | 2024-06-28 | 远大赛威信生命科学(南京)有限公司 | 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途 |
| WO2025076792A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Product Co., Ltd. | Methods of preparing norovirus vaccine with low amounts of adjuvant |
| WO2025077799A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Products Co., Ltd. | Method of preparing norovirus vaccine without adjuvant |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| AU1893592A (en) | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
| JPH07509122A (ja) | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレター，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法 |
| WO1994005700A2 (en) | 1992-09-07 | 1994-03-17 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| JP3863559B2 (ja) | 1994-05-16 | 2006-12-27 | メルク エンド カンパニー インコーポレーテッド | 乳頭腫ウィルスワクチン |
| US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5834015A (en) * | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
| US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| JP4598201B2 (ja) | 1997-04-08 | 2010-12-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 安定化ヒトパピローマウイルス製剤 |
| EP0980257A1 (en) | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| AU760633B2 (en) | 1998-08-14 | 2003-05-22 | Merck Sharp & Dohme Corp. | Process for purifying human papillomavirus virus-like particles |
| WO2000035479A1 (en) | 1998-12-17 | 2000-06-22 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
| DE60040727D1 (de) * | 1999-02-05 | 2008-12-18 | Merck & Co Inc | Menschliche papillomavirus impfstoff-formulierungen |
| ES2398413T3 (es) | 1999-06-22 | 2013-03-19 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Kit de detección de SRSV |
| JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体 |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| WO2003068163A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
| GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7135180B2 (en) | 2002-04-11 | 2006-11-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| WO2003103605A2 (en) | 2002-06-07 | 2003-12-18 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| CA2488856A1 (en) | 2002-06-20 | 2003-12-31 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
| ATE426412T1 (de) | 2003-01-30 | 2009-04-15 | Novartis Vaccines & Diagnostic | Adjuvante influenza-vakzine |
| US20040213745A1 (en) | 2003-02-20 | 2004-10-28 | Vincent Sullivan | Powder formulations of rSEB for improved vaccination |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| WO2005032457A2 (en) | 2003-07-21 | 2005-04-14 | Boyce Thompson Institute For Plant Research, Inc. | Vectors and methods for immunization against norwalk virus using transgenic plants |
| EP1670824A2 (en) | 2003-09-24 | 2006-06-21 | Montana State University | Norovirus monoclonal antibodies and peptides |
| WO2005037223A2 (en) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| JP4993301B2 (ja) | 2004-10-20 | 2012-08-08 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US20060177468A1 (en) | 2005-01-05 | 2006-08-10 | Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine | Delivery vehicles, bioactive substances and viral vaccines |
| EP1846439A2 (en) | 2005-01-31 | 2007-10-24 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| EP1868642B1 (en) | 2005-03-18 | 2013-05-08 | Cytos Biotechnology AG | Cat allergen fusion proteins and uses thereof |
| WO2007053188A2 (en) | 2005-06-01 | 2007-05-10 | Dow Global Technologies, Inc. | Production of multivalent virus like particles |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
| JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスｇｉの高感度検出方法 |
| US20080029915A1 (en) * | 2006-08-02 | 2008-02-07 | Courtoy Nv | Rotary tablet press |
| SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| DK2134360T3 (en) * | 2007-03-14 | 2016-02-22 | Takeda Vaccines Inc | Purification of virus-like particle |
| AU2008299589B2 (en) | 2007-09-12 | 2014-06-26 | Australian Centre For Plant Functional Genomics Pty Ltd | Plant seed active transcriptional control sequences |
| US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| JP2010539192A (ja) * | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
| AU2009279456B2 (en) | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| JP2012515752A (ja) * | 2009-01-22 | 2012-07-12 | ファーマシーネ，インコーポレイテッド | 安定なワクチン組成物とその使用方法 |
| SI2396030T1 (sl) * | 2009-02-10 | 2015-12-31 | Novartis Ag | Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo |
| US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| KR20120125627A (ko) * | 2010-01-21 | 2012-11-16 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | 칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공 |
| AU2011258165B2 (en) * | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| CA2841356C (en) | 2011-07-11 | 2022-03-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| ES2952064T3 (es) | 2015-12-16 | 2023-10-26 | Walter & Eliza Hall Inst Medical Res | Inhibición de la proteína SH2 inducida por citocinas en células NK |
| JP7181862B2 (ja) | 2016-10-18 | 2022-12-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 腫瘍浸潤リンパ球および治療の方法 |
| MX2020011697A (es) | 2018-05-03 | 2020-12-10 | Univ Texas | Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario. |
| US20210308249A1 (en) | 2018-08-20 | 2021-10-07 | Takeda Vaccines, Inc. | Vlp formulations |
| AR117462A1 (es) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| EP3924467A1 (en) | 2019-02-15 | 2021-12-22 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
-
2012
- 2012-07-11 CA CA2841356A patent/CA2841356C/en active Active
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/pl unknown
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/zh active Pending
- 2012-07-11 EA EA201490258A patent/EA029470B1/ru not_active IP Right Cessation
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/es active Active
- 2012-07-11 MX MX2018006816A patent/MX379496B/es unknown
- 2012-07-11 MX MX2014000411A patent/MX356586B/es active IP Right Grant
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/en not_active Ceased
- 2012-07-11 EA EA202090699A patent/EA202090699A3/ru unknown
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 PH PH1/2021/551773A patent/PH12021551773A1/en unknown
- 2012-07-11 HK HK14112697.5A patent/HK1199202A1/xx unknown
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/ja active Active
- 2012-07-11 PH PH1/2014/500093A patent/PH12014500093A1/en unknown
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/es active IP Right Grant
- 2012-07-11 EA EA201792407A patent/EA035442B1/ru not_active IP Right Cessation
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/zh active Pending
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/da active
- 2012-07-11 PL PL12811916T patent/PL2731621T3/pl unknown
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/ko active Active
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/pt not_active Application Discontinuation
- 2012-07-11 CR CR20190540A patent/CR20190540A/es unknown
- 2012-07-11 ES ES17199372T patent/ES2926487T3/es active Active
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/en active Active
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/en active Pending
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/en active Active
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/zh active Pending
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-11-07 UA UAA201401321A patent/UA117732C2/uk unknown
-
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
-
2014
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/es unknown
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/es unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/fr unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/es unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/es unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/zh unknown
-
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
-
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/ja active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
-
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515B1/en unknown
-
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
-
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/es unknown
-
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501515B1 (en) | Parenteral novovirus vaccine formulations | |
| MY197723A (en) | Vaccine compositions for the prevention of dengue virus infection | |
| PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
| MX2012009581A (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| NZ627980A (en) | Pharmaceutical compositions containing dimethyl fumarate | |
| MY172578A (en) | Oral dosing of glp-1 compounds | |
| IN2012DN02736A (https=) | ||
| MX2013013801A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
| EP2825196A4 (en) | ADJUVANZ AND VACCINE COMPOSITIONS | |
| MX346596B (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
| IL231421A (en) | Lupane and its similar compounds are preserved in position 3ß by carboxy-alkyl-carbonyl-oxy and position 17- by (alkyl-conserved) amino, and also anti-HIV drug preparations containing them | |
| PH12017500304A1 (en) | Vaccine compositions against dengue virus diseases | |
| PH12013500784A1 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
| EP2694102A4 (en) | PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY | |
| EA032913B1 (ru) | Препараты производных пиримидиндиона | |
| EA201690378A1 (ru) | Вакцинные композиции против наркотической зависимости | |
| IN2013CH04314A (https=) | ||
| PH12015500708A1 (en) | Agent for enhancing immunity containing glutathione | |
| IN2013MU02059A (https=) | ||
| UA106111C2 (uk) | Спосіб отримання людського інтерферону з використанням наночастинок оксиду церію |